Stock Market Today, Jan. 15: ImmunityBio Surges After Anktiva Revenue Jumps 700%

Core Insights - ImmunityBio's Anktiva has shown explosive sales growth, with a projected revenue increase from $15 million in 2024 to $113 million in 2025, representing a 700% growth year-over-year [2][5] - The stock price of ImmunityBio surged by 30.80% to close at $3.95, driven by strong preliminary earnings results and ongoing demand trends for Anktiva [2][5] - Recent approvals and positive clinical data for Anktiva in new indications, such as non-small cell lung cancer, indicate significant geographic expansion potential for the company [6] Company Performance - ImmunityBio's market capitalization stands at $3.0 billion, with a gross margin of 80.41% [2] - The trading volume reached 70.4 million shares, significantly above the three-month average of 13 million shares, indicating heightened investor interest [3] - The stock has experienced a dramatic decline of 89% since its IPO in 2015, highlighting its volatile history [3] Market Context - The S&P 500 and Nasdaq Composite saw minor gains of 0.27% and 0.25% respectively, while ImmunityBio outperformed its biotechnology peers, such as Incyte and Vertex Pharmaceuticals, which experienced declines [4]